Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207679 | 0.87 | NOS1 (0.44) | NOS1DYRK1AALDH1A1HPGDPSMB8 | |
| SCHEMBL2438007 | 0.77 | KIF11 (0.34) | NOS1ALDH1A1HPGDPOLBHSD17B10 | |
| SCHEMBL6217817 | 0.77 | MAPT (0.42) | DYRK1AALDH1A1HPGDPOLBHSD17B10 | |
| SCHEMBL208155 | 0.77 | DYRK1A (0.42) | NOS1DYRK1AALDH1A1AHRRAB9A | |
| SCHEMBL406467 | 0.70 | MAPT (0.50) | NOS1ALDH1A1HPGDPSMB8POLB | |
| SCHEMBL315671 | 0.65 | MAP2K4 (0.37) | NOS1ALDH1A1HPGDPSMB8ALOX15 | |
| SCHEMBL14485029 | 0.64 | GPR84 (0.42) | AHRCMA1POLBALOX15F7 | |
| SCHEMBL207651 | 0.62 | AHR (0.43) | NOS1DYRK1AALDH1A1HPGDPSMB8 | |
| SCHEMBL154970 | 0.62 | — | — | |
| SCHEMBL2439787 | 0.61 | ALDH1A1 (0.47) | DYRK1AALDH1A1HPGDPSMB8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | claimed |
| EP-3946345-A1 | METHODS OF TREATING NEUROPATHIC PAIN | Intra-Cellular Therapies, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113905737-A | Method of treating neuropathic pain | 细胞内治疗公司 | 2022-01-07 | — | — | CN | claimed |
| EP-3914235-A2 | METHODS OF TREATING ADDICTION | Intra-Cellular Therapies, Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113329742-A | Method for treating addiction | 细胞内治疗公司 | 2021-08-31 | — | — | CN | claimed |
| WO-2020206391-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-10-08 | — | — | WO | claimed |
| WO-2020154519-A2 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2020132605-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-25 | — | — | WO | claimed |
| WO-2016007837-A1 | CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-01-14 | — | — | WO | claimed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | claimed |
| EP-2680844-A2 | AMINO-QUINOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-08 | — | — | EP | claimed |
| EP-2566477-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-03-13 | — | — | EP | claimed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| WO-2012122011-A2 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | claimed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | claimed |
| CN-101827849-A | Novel compounds of reverse turn mimetics and the use thereof (1) | CHOONGWAE PHARMA CORP | 2010-09-08 | — | — | CN | claimed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | NOS1 1617/4885DYRK1A 225/4885ALDH1A1 1337/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | NOS1 677/4885DYRK1A 2035/4885ALDH1A1 1029/4885 |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | NOS1 1142/4885DYRK1A 431/4885ALDH1A1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.